Graybug Vision (GRAY) Stock Price, News & Analysis

Company Overview

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases of the back of the eye. Founded in 2014 and headquartered in Redwood City, California, the company leverages its proprietary Depot™ sustained-release technology platform to create long-lasting intraocular treatments intended to reduce the treatment burden for patients living with chronic retinal diseases.

The company’s lead product candidate, GB-102, is a sustained-release formulation of sunitinib malate designed for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). GB-102 is delivered via a single intravitreal injection and is engineered to provide therapeutic levels of active drug over multiple months. In addition, Graybug is advancing GB-401, a sustained-release therapy targeting geographic atrophy secondary to dry AMD, with the goal of addressing unmet needs in retinal degenerative conditions.

Graybug Vision operates primarily in the United States but is actively engaging with regulatory authorities in Europe and other regions to support global development and potential commercialization. The company maintains a robust intellectual property portfolio covering its Depot™ platform and pipeline candidates, and collaborates with contract manufacturing organizations for clinical supply and scale-up activities. Key executive leadership includes Jeffrey S. Grossman as Chief Executive Officer and Dr. Paul Ashton as Chief Medical Officer, supported by a management team experienced in ophthalmology drug development and regulatory strategy.

Since its initial public offering on the Nasdaq Stock Market in 2019 under the ticker “GRAY,” Graybug Vision has focused its efforts on advancing clinical programs through Phase 1/2 and Phase 2 studies. The company continues to work closely with investigators, patient advocacy groups and global health authorities to accelerate development timelines and bring novel treatments to patients affected by vision-threatening eye diseases.

Key Stats

• Today's Range: $2.53 to $3.20
• 50-Day Range: $1.43 to $2.52
• 52-Week Range: $5.00 to $22.12
• Volume: 297,328 shs
• Average Volume: 2,165 shs
• Market Capitalization: $4.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRAY Stock Analysis - Frequently Asked Questions

How have GRAY shares performed this year?

Graybug Vision's stock was trading at $3.29 on January 1st, 2025. Since then, GRAY shares have decreased by 23.4% and is now trading at $2.52.

How were Graybug Vision's earnings last quarter?

Graybug Vision, Inc. (NASDAQ:GRAY) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($5.32) EPS for the quarter, missing analysts' consensus estimates of ($5.18) by $0.14.

When did Graybug Vision's stock split?

Graybug Vision's stock reverse split before market open on Monday, March 20th 2023.The 1-14 reverse split was announced on Monday, March 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Graybug Vision IPO?

Graybug Vision (GRAY) raised $75 million in an IPO on Friday, September 25th 2020. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers.

How do I buy shares of Graybug Vision?

Shares of GRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Graybug Vision own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Graybug Vision investors own include Tesla (TSLA), Plug Power (PLUG), Athenex (ATNX), NIO (NIO), Moderna (MRNA), Pinterest (PINS).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRAY
• CIK: 1534133
• Web: www.graybug.com
• Phone: N/A
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($24.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.61%
• Return on Assets: -71.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.73
• Quick Ratio: 10.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 20,250,000
• Market Cap: $3.96 million
• Optionable: Not Optionable
• Beta: 1.20